HDAC9 and melanoma: For example, synergy between JQ1 and the BCL2 inhibitor navitoclax (ABT-263) against MYCN-amplified SCLC has been reported [49] and preclinical studies combining BET inhibitors and HDAC inhibitors showed synergistic activity against urothelial carcinoma cell lines, melanoma cells, and murine models of pancreatic ductal adenocarcinoma [50, 51, 60].